All Clinical Trials
Mater conducts clinical trials in a range of therapeutic areas including Cance, Nerouology, Medicine, Orthopaedics Surgery and Acute Care, and Mothers' and Babies Health. Clinical trials are an essential component of helathcare. They provide the evidence to evaluate the safety and efficacy of new treantments and diagnositics, and provide alternative treatment options for patients with unmet needs.
Phenylketonuria (PKU): An early phase trial of a new treatment for PKU
This study is trialing a novel drug, called JNT-517, which works by increasing excretion of phenylalanine in the urine to reduce circulating levels in the blood.
Pilaster - New add on therapy to help treat chronic obstructive pulmonary disease with chronic bronchitis
Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With Chronic obstructive pulmonary disease (COPD) and Chronic Bronchitis.
PUERTA: A novel treatment for patients in acute respiratory distress
ALT-100-002: Pioneering the Utility of eNAMPT-Reducing Therapies in Acute Respiratory Distress Syndrome [ARDS]/ ventilator-induced lung injury.
QUASAR Jr
The purpose of this study is to evaluate the effectiveness of guselkumab in pediatric participants with moderately to severely active ulcerative colitis through open label induction and through maintenance therapy among participants who were induction responders.
RAISE A clinical trial of a ganaxalone in status epilepticus
RC-48
The trial is testing a potential new treatment called disitamab vedotin for Muscle-invasive Bladder Cancer.
RESOLUTION – Preventative treatment for migraine in patients with medication overuse headaches
Evaluating eptinezumab with a brief educational intervention for prevention of migraine in patients with migraine and medication overuse headache.
Ridstress2 - Improving outcomes for women and small babies.
SNDX-6352-0506 - Axatilimab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Axatilimab is a “monoclonal antibody”, which is an antibody manufactured in a laboratory. It is designed to specifically block a protein believed to be involved in lung fibrosis. By blocking this protein, Axatilimab may slow or stop the progression of IPF.
Teton 2 - New IPF Treatment
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with IPF